MDM2 and neuroblastoma: The drug response pattern observed across tumour types matched well with our MI-773 and Nutlin-3a internal data: leukaemia, lymphoma, melanoma, neuroblastoma, mesothelioma, and renal cancer were the most sensitive tumour types to MDM2 inhibition.